Methyl 2-ethylnonanoate | 56682-35-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl 2-ethylnonanoate
• CAS: 56682-35-0
• 化学式: C₁₂H₂₄O₂
• 分子量: 200.32
• InChiKey: WMRXZLMVHTVUNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP3075726A1

  公开（公告）日：2016-10-05

  Provided is a compound having a formyl peptide receptor like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有类似甲酰肽受体 1（FPRL1）激动剂作用的化合物。 本发明涉及通式（I）所代表的化合物或其药理学上可接受的盐。本发明还涉及一种含有通式（I）所代表的化合物或其药理学上可接受的盐的药物组合物。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1646642A2

  公开（公告）日：2006-04-19
• US3933889A
  申请人：——

  公开号：US3933889A

  公开（公告）日：1976-01-20
• US4118404A
  申请人：——

  公开号：US4118404A

  公开（公告）日：1978-10-03
• [EN] INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE<br/>[FR] INHIBITEURS DE SERINES PROTEASES, EN PARTICULIER DE LA PROTEASE NS3-NS4A DU VHC
  申请人：VERTEX PHARMA

  公开号：WO2005007681A2

  公开（公告）日：2005-01-27

  The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by15 administering a pharmaceutical composition comprising a compound of this invention.